The PE Ratio as of November 2024 (TTM) for Kezar Life Sciences, Inc. (KZR) is -0.57

According to Kezar Life Sciences, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.57. This represents a change of -88.88% compared to the average of -5.13 of the last 4 quarters.

Kezar Life Sciences, Inc. (KZR) Historical PE Ratio (quarterly & annually)

How has KZR PE Ratio performed in the past?

The mean historical PE Ratio of Kezar Life Sciences, Inc. over the last ten years is -120.14. The current -0.57 PE Ratio has changed -52.55% with respect to the historical average. Over the past ten years (40 quarters), KZR's PE Ratio was at its highest in in the June 2024 quarter at -0.49. The PE Ratio was at its lowest in in the June 2017 quarter at -307.33.

Kezar Life Sciences, Inc. (KZR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Kezar Life Sciences, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Kezar Life Sciences, Inc. (KZR) Average PE Ratio

How has KZR PE Ratio performed in the past?

The current PE Ratio of Kezar Life Sciences, Inc. (KZR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Kezar Life Sciences, Inc. (KZR) PE Ratio vs. Peers

How is KZR’s PE Ratio compared to its peers?

Kezar Life Sciences, Inc.’s PE Ratio is greater than Century Therapeutics, Inc. (-0.79), greater than Mineralys Therapeutics, Inc. (-4.06), greater than Nkarta, Inc. (-1.63), greater than NGM Biopharmaceuticals, Inc. (-1.35), greater than Surrozen, Inc. (-0.66), less than Bolt Biotherapeutics, Inc. (-0.34), greater than Larimar Therapeutics, Inc. (-6.07), greater than Keros Therapeutics, Inc. (-11.12), greater than Lyell Immunopharma, Inc. (-1.19), greater than Cullinan Oncology, Inc. (-5.10), greater than Monte Rosa Therapeutics, Inc. (-5.83), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Revolution Medicines, Inc. (-16.70), greater than Foghorn Therapeutics Inc. (-5.38), greater than Shattuck Labs, Inc. (-0.69), greater than Kymera Therapeutics, Inc. (-20.45), greater than Nurix Therapeutics, Inc. (-9.07), greater than Design Therapeutics, Inc. (-6.66), greater than Werewolf Therapeutics, Inc. (-1.34), greater than Ikena Oncology, Inc. (-1.38), greater than Stoke Therapeutics, Inc. (-6.11),

Build a custom stock screener for Kezar Life Sciences, Inc. (KZR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Kezar Life Sciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Kezar Life Sciences, Inc. (KZR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Kezar Life Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.